Introduction
============

Pancreatic cancer (PC) patients have a 5-year survival rate of lower than 10% ([@ref-27]). According to the American Cancer Society, the average age of PC patients at diagnosis is 70 years. Less than 3% of PC patients are under the age of 45 years at diagnosis ([@ref-29]), which was defined as very early onset PC (VEOPC) ([@ref-20]). Duo to its rareness, few data were reported regarding the clinicopathological features and treatment response of VEOPC patients ([@ref-10]; [@ref-15]; [@ref-17]; [@ref-20]; [@ref-26]).

The identification of prognostic factors of PC might improve the prediction of the survival and the selection of therapy for PC patients. The well-known PC prognostic factors comprised resection margins, lymph nodes status and lymph node ratio, perineural and blood vessel invasion, tumor localization and body mass index (BMI) and treatment such as chemotherapy ([@ref-6]; [@ref-19]). However, whether age is a prognostic factor of PC is currently controversial. Some studies found "younger" PC patients (with different definition of age \<45 years, age \<50 years, age \<60 years and age \<70 years) had better overall survival (OS) than the older PC patients ([@ref-5]; [@ref-12]; [@ref-24]; [@ref-28]). While the other studies found younger age (with different definition of age \<65 years and age \<70 years [@ref-4]; [@ref-21]; [@ref-32]) was not associated with the survival of PC patients. It should be noted that these studies had a limited number of VEOPC patients or did not treat the VEOPC as a group.

Nomograms are a valuable tool to use different clinical variables to determine a statistical prognostic model that generates a probability of clinical outcomes for a single patient ([@ref-3]). Nomograms have been applied in various types of cancers ([@ref-8]; [@ref-14]; [@ref-18]; [@ref-23]). Nowadays, nomograms are commonly used to estimate prognosis in oncology and medicine, which fit the trend of personalized medicine ([@ref-3]). It is worth constructing a nomogram for predicting the prognosis of VEOPC patients.

Pancreatic adenocarcinoma (PDAC) is the main type of PC, which has a worse prognosis than other histology types. The current study selected PDAC patients as our cohort. It should be noted that the competing event of death is widely existing in the prognostic analysis of cancer. The failure to account for such competing events, such as the Kaplan--Meier method and standard Cox proportional hazards regression analysis, might result in an overestimate of the cumulative incidences ([@ref-25]). The competing risk model considers both the disease-specific death and other causes of death, which was fit to the analysis in the presence of competing risk events ([@ref-16]). The competing risk analysis was often missed in previous studies when included with very aged PC patients. The aim of our study was to use competing risk model to estimate the prognostic value of age in PDAC patients and construct competing nomogram for cancer--specific death prediction of VEOPC patients by using the data from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute of the United States, which currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 34.6 percent of the United States population ([@ref-30]).

Methods
=======

Cohort selection
----------------

The cohort was selected by SEER\*Stat 8.3.5 software with the following criteria: (1) it should be a primary PDAC patients (ICD-O-3 histology codes 8140 and 8500) registered equal or after year of 2004; (2) it should be a patient who has a survival time over than 0 month with records of survival status; (3) it should have at least one year follow up time to capture enough events to ensure a meaningful analysis. We also excluded few patients with unclear information of race, surgery, number of regional lymph nodes examined, radiotherapy and marital status. Finally, we excluded 1 patient with cancer in the islets of langerhans. The detailed data selection process was shown in [Fig. S1](#supp-4){ref-type="supplementary-material"}.

Study variables and endpoints
-----------------------------

We included 14 variables into our analysis, which were listed as the follows: age at diagnosis, sex (Females and males), race (Caucasian, African American, American Indian/Alaska Native and Asian or Pacific Islander), tumor location (Head of pancreas, body of pancreas, tail of pancreas, pancreatic duct, other specified parts of pancreas, overlapping lesion of pancreas and Pancreas, NOS (Not otherwise specified)), surgery experience (No surgery, local or partial pancreatectomy, local or partial pancreatectomy and duodenectomy, total pancreatectomy with or without gastrectomy or duodenectomy, pancreatectomy NOS or surgery NOS), tumor size, LNR (Lymph nodes ratio, which is defined as the ratio of the number of positive lymph nodes to the total number of lymph nodes examined), 6th American Joint Committee on Cancer (AJCC) tumor TNM stage, grade, radiotherapy and chemotherapy experience and marital status. The value of age at diagnosis, tumor size and LNR were classified into small categorical variables to fit the linear assumption. The widowed or single (Never married or having a domestic partner) or divorced or separated patients was defined as "Single". The median observed survival time was referred to median follow-up time.

Statistical analyses
--------------------

The difference of each variable between VEOPC and other PC patients was evaluated by Chi-Squared tests. Cumulative incidences of death (CID) was estimated for deaths caused by cancer or other reasons by using the cumulative incidences function (CIF) analysis. Multivariate SH model was used to assess the cancer specific survival (CSS). All the variables were included in the multivariate analysis. Hazard ratio (HR) and 95%confidence index (95%CI) were calculated.

Multivariate SH model-based nomogram was constructed by multivariate logistic regression model to predict the 6 months, 12 months, 18 months and 24 months cancer specific death of VEOPC patients. The internal validation of nomogram was performed by discrimination and calibration with 1,000 time bootstraps ([@ref-3]). The discrimination was estimated by the area under the curve of receiver operating characteristic curve (AUC, which was also referred as C-statistics). The AUC ranges from 0.5--1.0, with 0.5 indicates the outcomes is totally random and 1.0 indicates the perfect discrimination. The calibration was assessed by calibration curves, which shows how close the nomogram estimated risk was to the observed risk. All the statistical analyses were performed by "R" version 3.6.0. The CIF test and multivariate SH analysis were performed by "R" package "cmprsk". The competing risk nomogram was constructed by "R" package "mstate" and plotted by "R" package "regplot". The calibration curve was drawn by "R" package "riskRegression". The AUC was calculated by "R" package "riskRegression" and plotted by "R" package "ggplot2". A two tailed *p*-value less than 0.05 was considered statistically significant.

Results
=======

Cohort selection
----------------

We included the patients diagnosed equal to or before 2015 to ensure an enough follow-up time. There were 1,386 VEOPC patients and 53,940 older PDAC patients (≥45 years). The median survival time of VEOPC and older patients were 9 and 7 months, respectively. Significant differences were found between VEOPC and other PC patients. The VEOPC patients had more males, fewer Caucasians, more surgery rates, fewer LNR, higher TNM stage, higher grade, more experience of chemotherapy and radiotherapy and fewer of married status (*p* \< 0.001, [Table 1](#table-1){ref-type="table"}) than the older patients. We also provided a table with characteristics for all patients ([Table S1](#supp-1){ref-type="supplementary-material"}). We divided the older patients into 4 groups with different age ranges (45--59 years, 60--69 years, 70--79 years and \>79 years) for further analysis.

Prognostic analysis of age in PDAC patients
-------------------------------------------

The CIF plot showed VEOPC patients had a decreased risk of cancer death than older patients (*p* \< 0.001, [Fig. 1A](#fig-1){ref-type="fig"}). Further subgroup analyses by surgery showed that VEOPC patients had better prognosis than the older patients whether they performed surgery or not (*p* \< 0.001, [Figs. 1B](#fig-1){ref-type="fig"}--[1C](#fig-1){ref-type="fig"}). Moreover, multivariate SH model with all the included variables showed that in unresectable PDAC patients, the VEOPC had better CSS than older patients. While in the resected PDAC patients, no significant difference was found between VEOPC and older patients ([Table 2](#table-2){ref-type="table"}).
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###### The demographic and treatment data of VEOPC and older PC (≥45 years) patients.

![](peerj-08-8412-g005)

  Characteristics                                                    VEOPC (*N* = 1,386)   Older PC (*N* = 5,3932)                      
  ------------------------------------------------------------------ --------------------- ------------------------- ------- ------- -- --
  **Sex**                                                                                                                               
  Male                                                               796                   57.4%                     27337   50.7%      
  Female                                                             590                   42.6%                     26595   49.3%      
  **Race**                                                                                                                              
  Caucasian                                                          1026                  74.0%                     43089   79.9%      
  African American                                                   207                   14.9%                     6522    12.1%      
  American Indian/Alaska Native                                      13                    0.9%                      287     0.5%       
  Asian or Pacific Islander                                          140                   10.1%                     4034    7.5%       
  **Location**                                                                                                                          
  Head of pancreas                                                   738                   53.2%                     29410   54.5%      
  Body of pancreas                                                   154                   11.1%                     6921    12.8%      
  Tail of pancreas                                                   182                   13.1%                     6458    12.0%      
  Pancreatic duct                                                    12                    0.9%                      319     0.6%       
  Other specified parts of pancreas                                  18                    1.3%                      805     1.5%       
  Overlapping lesion of pancreas                                     113                   8.2%                      4049    7.5%       
  Pancreas, NOS                                                      169                   12.2%                     5970    11.1%      
  **Surgery**                                                                                                                           
  No surgery                                                         1040                  75.0%                     41989   77.9%      
  Local or partial pancreatectomy                                    43                    3.1%                      1517    2.8%       
  Local or partial pancreatectomy and duodenectomy                   242                   17.5%                     8175    15.2%      
  Total pancreatectomy with or without gastrectomy or duodenectomy   50                    3.6%                      1978    3.7%       
  Pancreatectomy NOS or surgery NOS                                  11                    0.8%                      273     0.5%       
  **Tumor size (cm)**                                                                                                                   
  ≤2                                                                 144                   10.4%                     4883    9.1%       
  2 to 4                                                             524                   37.8%                     23278   43.2%      
  4 to 6                                                             333                   24.0%                     12388   23.0%      
  \>6                                                                104                   7.5%                      3840    7.1%       
  Unknown                                                            281                   20.3%                     9543    17.7%      
  **LNR**                                                                                                                               
  0                                                                  137                   9.9%                      4542    8.4%       
  ≤0.2                                                               126                   9.1%                      3983    7.4%       
  0.2--0.4                                                           57                    4.1%                      2180    4.0%       
  0.4--1                                                             55                    4.0%                      2116    3.9%       
  No nodes were examined                                             1011                  72.9%                     41111   76.2%      
  **T stage**                                                                                                                           
  T1-T2                                                              275                   19.8%                     11774   21.8%      
  T3-T4                                                              865                   62.4%                     33301   61.7%      
  Unknown                                                            246                   17.7%                     8857    16.4%      
  **N stage**                                                                                                                           
  NO                                                                 603                   43.5%                     26845   49.8%      
  N1                                                                 584                   42.1%                     19325   35.8%      
  Unknown                                                            199                   14.4%                     7762    14.4%      
  **M stage**                                                                                                                           
  M0                                                                 582                   42.0%                     26570   49.3%      
  M1                                                                 786                   56.7%                     25678   47.6%      
  Unknown                                                            18                    1.3%                      1684    3.1%       
  **Grade**                                                                                                                             
  I-II                                                               326                   23.5%                     11939   22.1%      
  III-IV                                                             256                   18.5%                     8755    16.2%      
  Unknown                                                            804                   58.0%                     33238   61.6%      
  **Chemotherapy**                                                                                                                      
  No                                                                 312                   22.5%                     20586   38.2%      
  Yes                                                                1074                  77.5%                     33346   61.8%      
  **Radiotherapy**                                                                                                                      
  No                                                                 1021                  73.7%                     42283   78.4%      
  Yes                                                                365                   26.3%                     11649   21.6%      
  **Marital status**                                                                                                                    
  Married                                                            768                   55.4%                     32013   59.4%      
  Single                                                             618                   44.6%                     21919   40.6%      

**Notes.**

All variables showed significant differences between VEOPC and older PC patients (*p* \< 0.001).

Independent prognostic factors of CSS of VEOPC
----------------------------------------------

As shown in [Table 3](#table-3){ref-type="table"}, multivariate SH model was used to find independent prognostic factors for the CSS of VEOPC patients. We found the female, race of Asian or Pacific Islander, PC located in pancreatic duct, no surgery, high LNR, high M stage, high grade, lack of chemotherapy, and single status were risk factors of the VEOPC patients (*P* \< 0.05).

![CIF plots of the association between age and the prognosis of PDAC patients.\
(A--C) The CIF plots of the association between age and the prognosis of all cohort (A), patients with surgery (B) or without surgery (C).](peerj-08-8412-g001){#fig-1}

Nomogram development and validation
-----------------------------------

The nomogram was constructed by multivariate SH model. A weighted total score calculated from each variable was used to estimate the 6 months, 12 months, 18 months and 24 months cancer specific death of VEOPC patients ([Fig. 2](#fig-2){ref-type="fig"}). The sex, race, location, surgery strategy, tumor size, LNR, TNM stage, grade, chemotherapy and marital status were found to be significantly important for the prognosis of VEOPC patients (Variables with asterisk in [Fig. 2](#fig-2){ref-type="fig"}). The calibration plots showed well correlation between observed CSS and nomogram predicted CSS ([Figs. 3A](#fig-3){ref-type="fig"}--[3D](#fig-3){ref-type="fig"}). Time dependent AUC plot suggested well discrimination of our nomogram (AUC ≤ 0.736, [Fig. 3E](#fig-3){ref-type="fig"}). Furthermore, we equally stratified the whole VEOPC into three groups based on their level of competing nomogram scores and performed a CIF analysis. The CIF plot ([Fig. 4](#fig-4){ref-type="fig"}) showed VEOPC with higher scores of our competing nomogram was at high risk of cancer related death. It indicated that our competing nomogram was useful for risk stratification of the prognosis of VEOPC patients. The detailed competing nomogram scores for all variables were listed in [Table S2](#supp-2){ref-type="supplementary-material"}).

Discussion
==========

No previous competing analysis was performed to analyze the prognostic difference between VEOPC and older PC patients. The current study used competing risk model to estimate the prognostic difference between VEOPC and older patients by using the data from SEER. We found that among the unresectable PDAC patients, the VEOPC had better CSS than older patients. And among resected PDAC patients, there was no significant prognostic difference between VEOPC and older patients. We also built the first competing nomogram for primary VEOPC patients with histology type of PDAC.
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###### Multivariate SH analysis of CSS for the association between age and the prognosis of PDAC patients.

We included all variables in the SH multivariate analysis.

![](peerj-08-8412-g006)

  Age (Years)   For the whole cohort     For patients with surgery   For patients without surgery                                      
  ------------- ------------------------ --------------------------- ------------------------------ ---------- ----------------------- -------------
  \<45          Reference                                            Reference                                 Reference               
  45--59        **1.08 (1.02--1.14)**    **0.010**                   0.98 (0.86--1.12)              7.50E−01   **1.10 (1.03--1.16)**   **0.003**
  60--69        **1.10 (1.04--1.17)**    **\<0.001**                 1.01 (0.89--1.15)              9.00E−01   **1.13 (1.06--1.20)**   **\<0.001**
  70--79        **1.16 (1.09\[-1.23)**   **\<0.001**                 1.04 (0.91--1.19)              5.70E−01   **1.19 (1.12--1.26)**   **\<0.001**
  \>79          **1.17 (1.10--1.24)**    **\<0.001**                 1.00 (0.87--1.17)              9.60E−01   **1.19 (1.12--1.27)**   **\<0.001**

**Notes.**

HRHazard ratio95% CI95% confidence index

Significant results (*p* \< 0.05) were bolded.
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###### Multivariate SH analyses of CSS for each variable in VEOPC patients.

We included all variables in the SH multivariate analysis.

![](peerj-08-8412-g007)

  Characteristics                                                    HR (95% CI)             *p* value
  ------------------------------------------------------------------ ----------------------- -------------
  **Sex**                                                                                    
  Male                                                               Reference               
  Female                                                             **0.87 (0.77--0.98)**   **0.021**
  **Race**                                                                                   
  Caucasian                                                          Reference               
  African American                                                   1.02 (0.84--1.23)       0.880
  American Indian/Alaska Native                                      1.00 (0.67--1.50)       1.000
  Asian or Pacific Islander                                          **1.54 (1.30--1.83)**   **\<0.001**
  **Location**                                                                               
  Head of pancreas                                                   Reference               
  Body of pancreas                                                   0.89 (0.73--1.08)       0.220
  Tail of pancreas                                                   1.07 (0.87--1.32)       0.530
  Pancreatic duct                                                    **2.01 (1.34--3.02)**   **0.001**
  Other specified parts of pancreas                                  0.65 (0.33--1.29)       0.220
  Overlapping lesion of pancreas                                     0.92 (0.72--1.18)       0.520
  Pancreas, NOS                                                      **1.28 (1.03--1.60)**   **0.025**
  **Surgery**                                                                                
  No surgery                                                         Reference               
  Local or partial pancreatectomy                                    **0.40 (0.26--0.61)**   **\<0.001**
  Local or partial pancreatectomy and duodenectomy                   **0.46 (0.36--0.60)**   **\<0.001**
  Total pancreatectomy with or without gastrectomy or duodenectomy   **0.41 (0.28--0.61)**   **\<0.001**
  Pancreatectomy NOS or surgery NOS                                  0.77 (0.36--1.64)       0.490
  **Tumor size**                                                                             
  ≤2 cm                                                              Reference               
  2 to 4                                                             1.07 (0.87--1.32)       0.510
  4 to 6                                                             1.11 (0.88--1.41)       0.360
  \>6                                                                1.28 (0.94--1.74)       0.110
  Unknown                                                            1.01 (0.78--1.32)       0.930
  **LNR**                                                                                    
  0                                                                  Reference               
  ≤0.2                                                               **1.39 (1.02--1.90)**   **0.037**
  0.2--0.4                                                           **1.80 (1.30--2.51)**   **\<0.001**
  0.4--1                                                             **1.90 (1.37--2.64)**   **\<0.001**
  No nodes were examined                                             **1.33 (1.04--1.70)**   **0.021**
  **T stage**                                                                                
  T1-T2                                                              Reference               
  T3-T4                                                              1.16 (0.98--1.37)       0.082
  Unknown                                                            0.95 (0.73--1.22)       0.680
  **N stage**                                                                                
  NO                                                                 Reference               
  N1                                                                 1.12 (0.95--1.31)       0.170
  Unknown                                                            **1.34 (1.09--1.66)**   **0.005**
  **M stage**                                                                                
  M0                                                                 Reference               
  M1                                                                 **1.48 (1.25--1.75)**   **\<0.001**
  Unknown                                                            1.09 (0.60--1.96)       0.780
  **Grade**                                                                                  
  I-II                                                               Reference               
  III-IV                                                             **1.29 (1.07--1.56)**   **0.007**
  Unknown                                                            1.09 (0.93--1.29)       0.290
  **Chemotherapy**                                                                           
  No                                                                 Reference               
  Yes                                                                **0.63 (0.53--0.76)**   **\<0.001**
  **Radiotherapy**                                                                           
  No                                                                 Reference               
  Yes                                                                1.09 (0.94--1.25)       0.250
  **Marital status**                                                                         
  Married                                                            Reference               
  Single                                                             **1.15 (1.02--1.30)**   **0.021**

**Notes.**

HRHazard ratio95% CI95% confidence index

Significant results (*p* \< 0.05) were bolded.

Age was observed as an independent prognostic factor for many cancers. Previous studies identified that younger patients had worse prognosis than older patients in colorectal cancer ([@ref-33]) and breast cancer ([@ref-7]) while younger patients had better prognosis than older patients in lung cancer ([@ref-2]), liver cancer ([@ref-36]) and prostate cancer ([@ref-22]). A study found that the \<45 years PDAC patients had better survival than \>70 years PDAC patients ([@ref-12]). Another study found \<50 years PDAC patients had no significant difference on prognosis when compared with their whole cohort ([@ref-31]). To be noted, these studies only included with limited samples. A SEER-based study found the risk of cancer-specific death decreases with age in resectable PDAC patients ([@ref-11]). However, we found the age was not an independent prognostic factor for resectable PDAC patients. This difference might be caused by the difference of inclusion criteria that our study included more variables in the multivariate SH model. We provided a detailed inclusion workflow in the [Fig. S1](#supp-4){ref-type="supplementary-material"}. We found the VEOPC patients, despite with a higher TNM stage, had a better CSS than the older patients in unresectable patients ([Table S1](#supp-1){ref-type="supplementary-material"}). It might be explained by the well accepted fact that younger patients had more tolerance to chemotherapy. Indeed, in the unresectable group, the VEOPC patients had a 17.5% higher rate to have chemotherapy than the older patients.

Males had higher rate of PC incidence in United States ([@ref-35]). We observed the males had 15% higher rate than the females in VEOPC. Previous study found males had worse prognosis than females in patients under 60 years but not in VEOPC patients ([@ref-20]). It might be caused by the sample size. Our study had much higher amount of VEOPC patients than this study and we found the males had worse CSS than females.

Marriage status was linked to the improvements in cardiovascular, endocrine, immune function, and cancer prognosis ([@ref-1]; [@ref-9]; [@ref-13]). Previous study observed that unmarried patients were at significantly higher risk of presentation with metastatic cancer, undertreatment, and death resulting from their cancer ([@ref-1]). We found the VEOPC patients with married status had better CSS than patients with single status, which provided new hint to the association between support care and cancer prognosis.

![Nomogram for predicting 6 months, 12 months, 18 months and 24 months cancer-specific death of VEOPC patients.\
The nomogram is used by summing the points identified on the top scale for each independent variable and drawing a vertical line from the total points scale to the 6 months, 12 months, 18 months and 24 months cancer specific death to obtain the probability of survival. The total points projected to the bottom scale indicate the probability of the 6 months, 12 months, 18 months and 24 months cancer specific death. Sex: 1 = Male, 2 = Female; Race: 1 = Caucasian, 2 = African American, N = Other race; Location: 250 = Head of pancreas, 251 = Body of pancreas, 252 = Tail of pancreas, 253 = Pancreatic duct, 257 = Other specified parts of pancreas, 258 = Overlapping lesion of pancreas, 259 = Pancreas, NOS; Surgery, 0 = No surgery, 1 = Local or partial pancreatectomy, 2 = Local or partial pancreatectomy and duodenectomy, 3 = Total pancreatectomy with or without gastrectomy or duodenectomy, 4 = Pancreatectomy NOS or surgery NOS; Tumor size: 2 = \<two cm, 4 = two cm to four cm, 6 = four cm to six cm, 8 = \>6 cm, 9 = Unknown; LNR: 0 = 0, 1 = \<0.2, 2 = 0.2--0.4, 3 = \>0.4, 4 = No nodes were examined; T stage: 1 = T1-T2, 2 = T3-T4, 9 = Unknown; N stage: 0 = NO, 1 = N1, 9 = Unknown; M stage: 0 = M0, 1 = M1, 9 = Unknown; Grade: 1 = I-II, 2 = III-IV, 9 = Unknown; Chemotherapy: 0 = none/unknown and 1 = yes; Radiotherapy: 0 = none/unknown or refused, 1 = beam radiation or combination of beam with implants or isotopes or radiation with method or source not specified or radioactive implants or radioisotopes and N = Recommended, unknown if administered; Marital status: 0 = married; 1 = widowed or single (never married or having a domestic partner) or divorced or separated. The asterisk indicates significance.](peerj-08-8412-g002){#fig-2}

Our SH model based nomogram was well validated by discrimination and calibration. The variables included in our nomogram were easy to be obtained, allowing a feasible translation into the future clinical use. To be noted, we included both the significant variables and the insignificant variables into our nomogram, since if a nomogram only includes statistically significant variables, it might tend to exert an inappropriately large influence, leading to falsely narrowed confidence intervals, which would make this nomogram appear more accurate than it is ([@ref-34]). Patients with higher competing nomogram scores of our study were found to have higher CID, indicating that our nomogram was useful for risk stratification of the prognosis of VEOPC patients.

![Calibration curves and AUC plots for internal validation of SH based nomograms.\
The calibration plots for 6 months (A), 12 months (B) , 18 months (C) and 24 months (D) cancer specific death prediction of VEOPC patients; The *x*-axis shows the nomogram predicted probability while the *y*-axis is the actual survival estimated by the SH method, the black thick line overlaps the grey line indicating near perfect calibration; (E) time dependent AUC plots of SH-based nomograms.](peerj-08-8412-g003){#fig-3}

Our study had some limitations. First, the detailed strategy of chemotherapy or radiotherapy was missed in current study as well as other therapies such as immunotherapy. Second, although the current nomogram was well validated by internal validation, there was a lack of an external validation by cohort other than SEER. Third, it should be noted that only factors available in the SEER registry were examined. The results from this study might only fit the population from United States. Fourth, our study has no exploration of molecular mechanism, which was of interest but cannot be conducted at this time with data currently available.

![CIF plots based on the competing nomogram scores for the VEOPC patients.\
The whole cohort of VEOPC patients were divided into three equally distributed groups. The groups were named "High", "Intermediate" and "Low" according to the levels of patients' competing nomogram scores.](peerj-08-8412-g004){#fig-4}

Conclusions
===========

The current study showed that for unresectable PDAC, VEOPC had better CSS than older patients. For the VEOPC patients, we built a SH model based nomogram to estimate their CSS. This nomogram was shown to have good discrimination and calibration.

Supplemental Information
========================

10.7717/peerj.8412/supp-1

###### The demographic and treatment data of the whole cohort

###### 

Click here for additional data file.

10.7717/peerj.8412/supp-2

###### The SH model based nomogram scores for each included variable in current study

###### 

Click here for additional data file.

10.7717/peerj.8412/supp-3

###### The demographic and treatment data of patients with or without surgery

###### 

Click here for additional data file.

10.7717/peerj.8412/supp-4

###### The data selection process of current study
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###### Raw data from the SEER database

The raw data shows all the PDAC patients who were finally included in current study after our selection. The detailed description of each variable could be found in SEER Research Data Record Description (Documentation Version: April 2018).
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